Yeran Bao, MD
Endocrinology, Diabetes & Metabolism · Walnut Creek, CANPI 1952317604
Payments from drug & device makers
Across 180 payments — averaging $3561.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$637K
- Novo Nordisk$816
- Amgen$536
- AstraZeneca$483
- Lilly USA, LLC$404
- Boehringer Ingelheim$319
- plus $1K from 22 others
Across 1 payment — averaging $6644.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7K
What the payments were for
- Food & beverage$3,921100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 6 | $637,073 |
| Novo Nordisk | 35 | $816 |
| Amgen | 17 | $536 |
| AstraZeneca(2 entities) | 22 | $483 |
| Lilly USA, LLC | 20 | $404 |
| Boehringer Ingelheim | 13 | $319 |
| Johnson & Johnson | 20 | $226 |
| Dexcom, Inc. | 3 | $208 |
| Boston Scientific | 1 | $140 |
| Radius Health, Inc. | 6 | $133 |
| Sanofi-aventis U.S. LLC | 7 | $132 |
| Abbott | 5 | $96 |
| Mannkind Corporation | 4 | $68 |
| Merck | 3 | $58 |
| Sequel Med Tech, LLC | 2 | $48 |
| Bayer | 2 | $46 |
| Novo Nordisk AS | 2 | $45 |
| AbbVie | 2 | $33 |
| Recordati_rare_diseases_inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Tandem Diabetes Care, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $18 |
| GSK | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Shionogi Inc | 1 | $16 |
| Pfizer | 1 | $15 |
| Insulet Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$164
- DEXCOM STELO GLUCOSE BIOSENSOR$164
- GENERAL VASCULAR INTERVENTION$140
- EVENITY$125
- Ozempic$124
- JARDIANCE$124
- RYBELSUS$122
- FARXIGA$119
How this compares
$641,053 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 297 | $531,571 |
| JardianceEmpagliflozin | 244 | $338,205 |
| TrulicityDulaglutide | 145 | $318,633 |
| FarxigaDapagliflozin Propanediol | 60 | $92,213 |
| MounjaroTirzepatide | 50 | $69,905 |
| RybelsusSemaglutide | 23 | $63,929 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $24,514 |
| TradjentaLinagliptin | 21 | $23,320 |
| JanuviaSitagliptin Phosphate | 22 | $18,755 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 110 | $17,120 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $14,174 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 26 | $11,579 |
| Humalog Kwikpen U-100Insulin Lispro | 46 | $10,726 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 101 | $10,448 |
| SynthroidLevothyroxine Sodium | 130 | $10,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $816 | $595,500320 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $404 | $393,682210 claims |
| Boehringer IngelheimJardiance, Tradjenta | $319 | $361,525265 claims |
| AstraZenecaFarxiga | $483 | $92,21360 claims |
| MerckJanuvia | $58 | $18,75522 claims |
| AbbVieSynthroid | $33 | $10,417130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Walnut Creek
- Mark ChristiansenWalnut Creek$22.9M
- Bonnie KimmelWalnut Creek$2.8M
- Jerrold OlefskySan Diego$26.5M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.